Merck bags EU approval for Keytruda chemo combo therapy for NSCLC
Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy
Continue readingCoverage of Global Pharma Industry News
Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy
Continue readingIrish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS
Continue readingMerck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA)
Continue reading